- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT01013883
The Darlington Retrospective Outpatient Study (DROPSY)
Long Term Outcomes in Patients With Heart Failure
Having heart failure means the heart is unable to pump blood around the body effectively. This reduces life expectancy and hinders normal daily activities. Heart failure affects about one million people in the UK; it is a major cause of death but it is often undetected and under-treated. If diagnosed and treated properly, the symptoms of heart failure can be well controlled and the length and quality of life can be improved.
Two drugs (called ACE-inhibitors and beta-blockers) help patients to live longer and suffer fewer consequences of heart failure. These drugs should be offered to all patients although this does not happen consistently for a variety of reasons. Doctors specialising in heart failure may help patients make better informed decisions about treatments and other aspects of care.
The purpose of this research is to explore the diagnosis, management and outcome of patients with heart failure who are referred to the one stop diagnostic heart failure clinic between Jan 2002 and Dec 2007. This study will provide vital information about diagnosis, initiation and titration of evidence based medication in the hospital, their follow in the primary care and subsequent patient outcome in terms of mortality.
연구 개요
상태
정황
상세 설명
Case notes of all the patients who were referred to the one stop diagnostic heart failure clinic during the period (Jan 2002- Dec 2007) will be reviewed and subjects who were found to have signs and symptoms of the Heart failure will be identified.
This cohort of patients will be further analysed and divided on the basis of Echocardiography (special scan of the heart that looks at the contraction, relaxation, and the flow of blood in the heart chambers) results into two groups.
- Those who have impaired contraction (systolic) function of there Left ventricle (left side chamber of the heart)
- Those who have normal contraction (systolic) function of the left ventricle.
Case notes of these patients will then be studied in detail with regards to their initial presentation, clinical examination, Electrocardiogram (electrical tracing of the heart) and chest X ray (picture of the heart and lungs) report.
These will be co-related with the findings and report of the Echocardiogram.
Once the diagnosis is established, uptake of evidence based medications (beta blockers, ACE inhibitors, spironolactone) and their titration up to the target dose at subsequent follow up visits in the heart failure clinic will be examined.
B) Phase 2 (General practice/ surgery phase)
This part of the study will be conducted at the GP surgery of the identified patient. This will involve accessing the data held at the GP practice with regards to
- Was heart failure treatment continued after discharge from the hospital clinic?
- If medications continued then for how long?
- If medications discontinued then why and by whom (Hospital/GP)?
- Current medications and the doses
- Admissions to the hospital if any?
- Any other co morbidities developed since discharge for the HF clinic?
- Outcome in terms of mortality
- The cause of death as specified on the death certificate
연구 유형
등록 (실제)
연락처 및 위치
연구 장소
-
-
Durham
-
Darlington, Durham, 영국, DL3 6HX
- Darlington Memorial Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
샘플링 방법
연구 인구
설명
Inclusion Criteria:
- 18 years and over attending heart failure clinic between 01/01/2002- 31/12/07
Exclusion Criteria:
- less than 18 years.
Pregnant females
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
코호트 및 개입
그룹/코호트 |
---|
systolic dysfunction
patients having left ventricular systolic dysfunction on echocardiography
|
distolic heart failure
patients with clinical heart failure and preserved LV systolic dysfunction
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
기간 |
---|---|
All Cause Mortality
기간: Patients would be followed up for average of 7 years
|
Patients would be followed up for average of 7 years
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
Cardiovascular Mortality
기간: Patients would be followed up for average of 7years
|
Patients would be followed up for average of 7years
|
|
Admission to Hospital for Any Cause
기간: During the follow up period of 7 years
|
Number of patients admitted to the hospital will be recorded
|
During the follow up period of 7 years
|
공동 작업자 및 조사자
수사관
- 수석 연구원: Rajender Singh, MD, county durham and darlington NHS trust
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
심부전에 대한 임상 시험
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan University of... 그리고 다른 협력자들아직 모집하지 않음심부전, 수축기 | 박출률이 감소된 심부전 | 심부전 New York Heart Association Class IV | 심부전 New York Heart Association Class III폴란드
-
Novartis Pharmaceuticals완전한핵심 연구의 12개월 치료 기간을 성공적으로 완료한 환자(de Novo Heart Recipients)는 EC-MPS 치료에 관심이 있었습니다.
-
University of WashingtonAmerican Heart Association완전한심부전,울혈 | 미토콘드리아 변경 | 심부전 New York Heart Association Class IV미국